Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2026)

Indivior Pharmaceuticals' Operating Leases history runs 6 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 53.33% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $14.0 million, a 53.33% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 31.25% from the prior year.
• Operating Leases declined to $14.0 million in Q1 2026 per INDV's latest filing, from $22.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $37.0 million in Q4 2022 and bottomed at $14.0 million in Q1 2026.
• The 5-year median for Operating Leases is $29.5 million (2025), against an average of $27.8 million.
• Across the five-year window, Operating Leases increased 2.78% in 2022 and plunged 53.33% in 2026, its largest moves.
• Year by year, Operating Leases stood at $37.0 million in 2022, then slipped by 8.11% to $34.0 million in 2023, then dropped by 5.88% to $32.0 million in 2024, then tumbled by 31.25% to $22.0 million in 2025, then plunged by 36.36% to $14.0 million in 2026.
• Per Business Quant, the three latest INDV Operating Leases figures stand at $14.0 million (Q1 2026), $22.0 million (Q4 2025), and $24.0 million (Q3 2025).